These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


309 related items for PubMed ID: 17194172

  • 1. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.
    Indermitte J, Burkolter S, Drewe J, Krähenbühl S, Hersberger KE.
    Drug Saf; 2007; 30(1):71-80. PubMed ID: 17194172
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia.
    Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M.
    Int J Clin Pharm; 2013 Dec; 35(6):1099-104. PubMed ID: 23974985
    [Abstract] [Full Text] [Related]

  • 3. Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?
    Park IW, Sheen SS, Yoon D, Lee SH, Shin GT, Kim H, Park RW.
    J Clin Pharm Ther; 2014 Feb; 39(1):61-8. PubMed ID: 24262001
    [Abstract] [Full Text] [Related]

  • 4. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T, Yamaga R, Fujita A, Itoh T.
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [Abstract] [Full Text] [Related]

  • 5. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.
    J Am Heart Assoc; 2017 Jul 19; 6(7):. PubMed ID: 28724651
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.
    Michel A, Martín-Pérez M, Ruigómez A, García Rodríguez LA.
    Eur J Heart Fail; 2015 Feb 19; 17(2):205-13. PubMed ID: 25581138
    [Abstract] [Full Text] [Related]

  • 7. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr 19; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 8. An investigation of the concomitant use of angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs and diuretics.
    Bucsa C, Moga DC, Farcas A, Mogosan C, Dumitrascu DL.
    Eur Rev Med Pharmacol Sci; 2015 Aug 19; 19(15):2938-44. PubMed ID: 26241552
    [Abstract] [Full Text] [Related]

  • 9. Risk calculation for hyperkalaemia in heart failure patients.
    Vereijken TL, Bellersen L, Groenewoud JM, Knubben L, Baltussen L, Kramers C.
    Neth J Med; 2007 Jun 19; 65(6):208-11. PubMed ID: 17587647
    [Abstract] [Full Text] [Related]

  • 10. Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs.
    Uijtendaal EV, Zwart-van Rijkom JE, van Solinge WW, Egberts TC.
    Eur J Clin Pharmacol; 2011 Sep 19; 67(9):933-40. PubMed ID: 21424384
    [Abstract] [Full Text] [Related]

  • 11. [Hyperkalemias].
    Radó J, Haris A.
    Orv Hetil; 1999 Nov 21; 140(47):2611-8. PubMed ID: 10613044
    [Abstract] [Full Text] [Related]

  • 12. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.
    Eur J Prev Cardiol; 2014 Mar 21; 21(3):299-309. PubMed ID: 24191305
    [Abstract] [Full Text] [Related]

  • 13. A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years.
    Muschart X, Boulouffe C, Jamart J, Nougon G, Gérard V, de Cannière L, Vanpee D.
    Acta Clin Belg; 2014 Aug 21; 69(4):280-4. PubMed ID: 24942977
    [Abstract] [Full Text] [Related]

  • 14. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
    Cruz CS, Cruz AA, Marcílio de Souza CA.
    Nephrol Dial Transplant; 2003 Sep 21; 18(9):1814-9. PubMed ID: 12937229
    [Abstract] [Full Text] [Related]

  • 15. Hyperkalaemia in diabetes: prevalence and associations.
    Jarman PR, Kehely AM, Mather HM.
    Postgrad Med J; 1995 Sep 21; 71(839):551-2. PubMed ID: 7479468
    [Abstract] [Full Text] [Related]

  • 16. Effect of prophylactic treatment with low-molecular-weight heparin bemiparin sodium on serum potassium levels: a prospective observational study.
    Torres OH, Hernandez N, Francia E, Barcelo M, Mateo J, Ruiz D.
    Drugs Aging; 2010 May 21; 27(5):399-406. PubMed ID: 20450237
    [Abstract] [Full Text] [Related]

  • 17. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
    Raml A, Schmekal B, Grafinger P, Biesenbach G.
    Dtsch Med Wochenschr; 2001 Nov 23; 126(47):1327-30. PubMed ID: 11719857
    [Abstract] [Full Text] [Related]

  • 18. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs.
    Bugge JF.
    J Intern Med; 1996 Oct 23; 240(4):249-51. PubMed ID: 8918517
    [Abstract] [Full Text] [Related]

  • 19. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R, Grancelli HO, Miriuka SG.
    Postgrad Med J; 2010 Mar 23; 86(1013):136-42. PubMed ID: 20237007
    [Abstract] [Full Text] [Related]

  • 20. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP, Dondi L, Andreotti F, Calabria S, Iacoviello M, Gorini M, Gonzini L, Piccinni C, Ronconi G, Martini N.
    Eur J Clin Invest; 2021 Aug 23; 51(8):e13551. PubMed ID: 33786826
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.